Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27824291 | 0.87 | KDM4E (0.67) | ATMKDM4EHTR2ATSHRTAAR1 | |
| SCHEMBL16961640 | 0.83 | ALDH1A1 (0.47) | ATMSIGMAR1CA2MAPK1MEN1 | |
| SCHEMBL19908629 | 0.82 | KDM4E (0.51) | ATMKDM4EHTR2ATSHRTAAR1 | |
| SCHEMBL21495043 | 0.80 | ALDH1A1 (0.47) | ATMKDM4ESIGMAR1CA2MEN1 | |
| SCHEMBL8288099 | 0.79 | HTR2A (0.49) | KDM4EHTR2ACYP19A1ALDH1A1CYP3A4 | |
| SCHEMBL29535675 | 0.79 | ATM (0.70) | ATMKDM4ESIGMAR1CA2TSHR | |
| SCHEMBL44393 | 0.79 | ATM (0.70) | ATMKDM4ESIGMAR1CA2TSHR | |
| SCHEMBL19409880 | 0.79 | ATM (0.70) | ATMKDM4ESIGMAR1CA2TSHR | |
| Hydrochloric Acid SCHEMBL9726669 | 0.77 | ATM (0.68) | ATMKDM4ESIGMAR1CA2CSNK2A1 | |
| SCHEMBL7938441 | 0.77 | KDM4E (0.46) | ATMKDM4EHTR2ATSHRCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323985-B1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-2349262-B1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2349262-B1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2350010-B1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2350010-B1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8592457-B2 | Isonicotinamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8349872-B2 | Tripyridyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010051236-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051237-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051236-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051237-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
| WO-2009020642-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | ATM 4850/4885KDM4E 1320/4885HTR2A 64/4885 |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | ATM 4845/4885KDM4E 1403/4885HTR2A 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.